Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews

[1]  D. Wingerchuk,et al.  Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews , 2023, Neurology and Therapy.

[2]  Jacqueline Palace,et al.  Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.

[3]  Gary R Cutter,et al.  Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial , 2019, The Lancet.

[4]  Mhs,et al.  Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder , 2019 .

[5]  J. Caro,et al.  Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D. , 2019, International journal of MS care.

[6]  F. Paul,et al.  Racial differences in neuromyelitis optica spectrum disorder , 2018, Neurology.

[7]  P. Wicks,et al.  Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. , 2017, Multiple sclerosis and related disorders.

[8]  B. Weinshenker,et al.  Neuromyelitis Spectrum Disorders , 2017, Mayo Clinic proceedings.

[9]  B. Kim,et al.  Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder , 2016, Journal of the Neurological Sciences.

[10]  M. Levy,et al.  Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[11]  Z. Shi,et al.  Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression , 2016, Journal of Neuroimmunology.

[12]  A. Methley,et al.  Development of a patient‐centred conceptual framework of health‐related quality of life in neuromyelitis optica: a qualitative study , 2015, Health expectations : an international journal of public participation in health care and health policy.

[13]  C. Young,et al.  Bladder and bowel dysfunction affect quality of life. A cross sectional study of 60 patients with aquaporin-4 antibody positive Neuromyelitis Optica spectrum disorder. , 2015, Multiple sclerosis and related disorders.

[14]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[15]  M. Papadopoulos,et al.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies , 2014, Nature Reviews Neurology.

[16]  A. Methley,et al.  Life on hold: the experience of living with neuromyelitis optica , 2014, Disability and rehabilitation.

[17]  J. Bennett,et al.  The Treatment of Neuromyelitis Optica , 2014, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[18]  F. Paul,et al.  Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) , 2013, Journal of Neurology.

[19]  S. Jarius,et al.  Aquaporin‐4 Antibodies (NMO‐IgG) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature , 2013, Brain pathology.

[20]  A. Traboulsee,et al.  Treatment of Neuromyelitis Optica: Review and Recommendations. , 2012, Multiple sclerosis and related disorders.

[21]  Jiwon Oh,et al.  Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System , 2012, Neurology research international.

[22]  B. Weinshenker,et al.  Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: [RETIRED] , 2011, Neurology.

[23]  Y. Itoyama,et al.  Pain in neuromyelitis optica and its effect on quality of life , 2011, Neurology.

[24]  Hongyu Zhou,et al.  Cognitive Function, Depression, Fatigue, and Activities of Daily Living in Patients With Neuromyelitis Optica After Acute Relapse , 2011, The International journal of neuroscience.

[25]  X. Montalban,et al.  EFNS guidelines on diagnosis and management of neuromyelitis optica , 2010, European journal of neurology.

[26]  B. Weinshenker,et al.  The spectrum of neuromyelitis optica , 2007, The Lancet Neurology.

[27]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[28]  P C O'Brien,et al.  The clinical course of neuromyelitis optica (Devic’s syndrome) , 1999, Neurology.

[29]  M. Levy,et al.  Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic , 2015, Current Treatment Options in Neurology.